| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Kenney Richard T | Chief Medical Officer | 100 OVERLOOK CENTER, SUITE 102, PRINCETON, | /s/ Richard T. Kenney | 21 Aug 2025 | 0001606653 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SONN | Warrant | Award | +86,505 | 86,505 | 30 Jun 2025 | Common Stock | 86,505 | $1.16 | Direct | F1 | |||
| transaction | SONN | Warrant | Award | +320,000 | 320,000 | 14 Jul 2025 | Common Stock | 320,000 | $1.25 | Direct | F2 | |||
| transaction | SONN | Series 5 Preferred Stock | Award | +200 | 200 | 14 Jul 2025 | Common Stock | 160,000 | $1.25 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | On June 30, 2025, the Reporting Person was issued warrants to purchase up to 86,505 shares of common stock, par value $0.0001 ("Common Stock") as partial consideration for a convertible note (the "Convertible Note") issued by the Company in favor of the Reporting Person in the principal amount of $200,000. The Convertible Note and warrants cannot be converted or exercised, respectively, to the extent that, after giving effect to such conversion or exercise, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Common Stock. |
| F2 | On July 14, 2025, the Reporting Person was issued warrants to purchase up to 320,000 shares of Common Stock upon the conversion in full of the Convertible Note. The warrants cannot be exercised to the extent that, after giving effect to such exercise, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Common Stock. |
| F3 | On July 14, the Reporting Person was issued 200 shares of Series 5 Preferred Stock, initially convertible at a conversion price of $1.25 per share upon the conversion in full of the Convertible Note. The Series 5 Preferred Stock cannot be converted to the extent that, after giving effect to such conversion, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Common Stock. The Series 5 Preferred Stock is perpetual and therefore has no expiration date. |